Compounded GLP-1s are a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist used for chronic weight management, along with a reduced calorie diet and increased physical activity, for people with an initial body mass index (BMI) of: 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)
Work with therapist or through self-monitoring to understand emotional eating patterns, stress responses, environmental cues Build support system
Numbness and tingling in hands and feet Poor balance Poor memory and dementia Mouth or tongue soreness Depression Deficiency is primarily due to issues of malabsorption, poor dietary intake and pernicious anemia
In clinical studies, participants typically used semaglutide for at least 68 weeks (about 16 months) to achieve significant and sustained weight loss
The daily dosing schedule of the ODT versus weekly injection is a trade-off